• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • How to Break the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

Mitsubishi Tanabe Pharma America – Oral Edaravone

Mitsubishi Tanabe Pharma America – oral edaravone

Background

Mitsubishi Tanabe Pharma America (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), founded in Japan in 1678. MTPC began studying an intravenous (IV) formulation (Radicava) of edaravone for ALS in 2001 and was approved for the treatment of ALS in Japan and South Korea in 2015, with subsequent approvals in Canada, Switzerland, China, Indonesia and Thailand.

Treatment with Radicava follows a regimen of initial treatment daily for 14 days, followed by a 14-day drug free period, and subsequent cycles of daily dosing for 10 of 14 days, followed by a 14-day drug free period.

During clinical development of IV Radicava, MTPA began a series of steps to determine if an oral suspension of edaravone could add to or replace the IV formulation for treatment of people living with ALS. First, bioequivalence had to be established to demonstrate that the oral edaravone could provide identical exposure as the established IV formulation. Multiple studies were performed.

The process began with a phase 1, open-label, single-dose crossover study in 42 participants, comparing 105 mg oral edaravone with 60 mg/hr IV formulation. Through comparing the pharmacokinetics (how it moves through the body) of both, it was concluded that the two formulations, at their respective doses, demonstrated equivalent exposure. This is published here.

Further, two additional phase 1 studies were performed. First, a placebo-controlled, randomized, single-blind study of increasing oral edaravone doses from 30 to 300 mg in 56 participants was completed. The second study, involving 84 participants, assessed whether oral edaravone interacted with other drugs and also examined potential pharmacokinetic differences between people of different racial backgrounds. In both cases, oral edaravone was considered safe and tolerable with no significant drug interaction effects or differences between racial backgrounds. These studies are published here.

Following bioequivalence, the next step was to undertake a large safety and tolerability trial of oral edaravone at the intended clinical dose. On December 9, 2021, MTPA announced the results of the global phase 3 clinical trial assessing safety and tolerability of oral edaravone over 24 weeks. The study enrolled 185 participants with ALS across 50 sites in the United States, Canada, Europe and Japan and included a long-term safety extension study of up to 96 weeks. No severe treatment emergent adverse events (TEAEs) were reported. It is expected that these results will be used in a regulatory submission for oral edaravone to be considered an equivalent treatment for ALS as Radicava, in the jurisdictions where it is currently approved.

On May 13, 2022, it was announced that the U.S. Food and Drug Administration (FDA) had approved RADICAVA ORS and it became available as of June 16. As of July 2022, edaravone oral suspension is also under review in Japan, Switzerland and Canada.

Simultaneously, MTPA has launched a phase 3b, multi-national, randomized, double-blind study to evaluate daily dosing of oral edaravone as compared to the current IV dosing regimen. Over 48 weeks, 380 participants either received oral edaravone once daily or for 10 days followed by an 18 day placebo suspension. This trial will evaluate a comparison of change in ALSFRS-R as the primary outcome measure and additional outcomes including slow vital capacity, quality of life (ALSAQ-40). It is set to read out in the second half of 2023.

Summary

Based on the available evidence, it is the opinion of the SAC that oral edaravone appears to be safe, tolerable and provides an equivalent drug exposure to intravenous Radicava. For those who currently access Radicava, it may provide a less burdensome alternative if approved.

International Alliance of ALS/MND Associations
August 2022


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Chris McCauley, Diagnosed 2015 - ALS Canada

    Chris McCauley, Diagnosed 2015 – ALS Canada

  • Margreth Burger-Saile, Diagnosed 2011 - ALS Schweiz, Switzerland

    Margreth Burger-Saile, Diagnosed 2011 – ALS Schweiz, Switzerland

  • Mike Rannie, ALS Canada, Diagnosed 2017, Canada

    Mike Rannie, ALS Canada, Diagnosed 2017, Canada

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • David Watson, MND Scotland, Diagnosed 2018, Scotland

    David Watson, MND Scotland, Diagnosed 2018, Scotland

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Mark Miller

    Mark Miller

  • Lachlan Terry, MND Australia, Diagnosed 2015, Australia

    Lachlan Terry, MND Australia, Diagnosed 2015, Australia

  • Jack Buzby, USA

    Jack Buzby, USA

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Elkin Ramiro Gaviria Muñoz, Diagnosed  December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Philip Brindle, MND Association, Diagnosed 2015, England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

  • Ian Roberts

    Ian Roberts

  • Angie Bordaen, Diagnosed 2014 - ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014 – ALS Liga België, Belgium

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Jeff Sutherland

    Jeff Sutherland
    jspic

  • Erwin Coppejans, Diagnosed 2007 - ALS Liga België, Belgium

    Erwin Coppejans, Diagnosed 2007 – ALS Liga België, Belgium

  • Alejandro Aquino, Diagnosed 2011 - Asociación ELA Argentina

    Alejandro Aquino, Diagnosed 2011 – Asociación ELA Argentina

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Duncan Bayly - MND Australia

    Duncan Bayly – MND Australia

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • David Bishop

    David Bishop

  • Art Eggert, USA

    Art Eggert, USA

  • Brian Lovell, Diagnosed 2011 - MND Australia

    Brian Lovell, Diagnosed 2011 – MND Australia

  • Marcel R. Wernard, Diagnosed 2016 - ALS Patients Connected, The Netherlands

    Marcel R. Wernard, Diagnosed 2016 – ALS Patients Connected, The Netherlands

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Daniel Hare

    Daniel Hare

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Eddy LeFrançois, Diagnosed 1992 - ALS Canada

    Eddy LeFrançois, Diagnosed 1992 – ALS Canada

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

  • Joy Blakeley, Diagnosed 2017 - MND Australia

    Joy Blakeley, Diagnosed 2017 – MND Australia

  • Steven Spencer, Diagnosed 2014 - MND New Zealand

    Steven Spencer, Diagnosed 2014 – MND New Zealand

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Willi Klein

    Willi Klein

  • Inta Grubb, Diagnosed 2014 - MND Australia

    Inta Grubb, Diagnosed 2014 – MND Australia

  • Charlie “Hark” Dourney, Diagnosed 2007 - Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 – Hark ALS, USA

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Susan Anderson, Diagnosed 2014 - Hope Loves Company, USA

    Susan Anderson, Diagnosed 2014 – Hope Loves Company, USA

  • Sally Pauls, Diagnosed 2006 - Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 – Les Turner ALS Foundation

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Ali Var, Turkey

    Ali Var, Turkey

  • Francisco Perez Palop, Diagnosed 2013 - FUNDELA, Spain

    Francisco Perez Palop, Diagnosed 2013 – FUNDELA, Spain

  • Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

Learn more about the March of Faces

Latest Tweets

  • Just now

Subscribe to our Bi-Monthly Newsletter

Fill out the form below to subscribe to the Alliance’s bi-monthly newsletter, packed with updates from members associations from around the world!

Footer

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login